• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

4DMedical Ltd Share Price Rises on New Medical Program [ASX:4DX]

Like 0

By Carl Wittkopp, Wednesday, 02 December 2020

4DMedical Ltd [ASX:4DX] rose 7.23% to trade at $2.52 at time of writing. The company announced a new research program with the University of Miami focused on functional lung imaging.

4DMedical Ltd [ASX:4DX] rose 7.23% to trade at $2.52 at time of writing.

The company announced a new research program with the University of Miami focused on functional lung imaging.

4DX ASX

Source: Optuma

What’s the new program about?

The new program will see 4DMedical and the University of Miami Health System establish the Functional Lung Imaging Research Program to advance breakthrough lung technologies.

The functional lung imaging research program will see the company use its proprietary XV Technology.

The goal is to improve treatment outcomes for those with lung disease.

This research is expected to deliver several studies that will include patients with diseases such as emphysema, cystic fibrosis, pulmonary hypertension, pulmonary embolism and lung cancer.

Henri Ford, MD, MHA, Dean and Chief Academic Officer of the Miller School of Medicine said:

‘Working with 4DMedical exemplifies our commitment to harness innovative technology in the quest for comprehensive treatment options for our patients.

‘Effective treatment protocols require an accurate understanding of the disease’s presentation.’

Where can this take 4DMedical?

4DMedical is only a new addiction to the All Ords [ASX:XAO], listing in August 2020.

While it may be new, there is a lot of potential with the respiratory diagnosis being a US$31 billion per annum global industry.

There is lot of room for growth.

Looking at the chart below, you can see the price sits above the level of $2.46 at time of writing. If it keeps moving up, the level of $2.76 may provide future resistance.

4dx asx

Source: Optuma

On the downside, should the price fall back then the levels of $2.46 and $2.09 may be enough to halt the fall.

4DMedical currently holds a market cap of $391.31 million. This year there is a larger than normal focus on lungs and respiratory health due to the COVID-19 pandemic.

Who knows what issues the virus will leave behind in the patients of COVID-19.

The studies being done and the technology from 4DMedical may become very important in the future.

Potentially sending the share price up.

Our publication, Money Morning, is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here.

Regards

Carl Wittkopp

For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Carl Wittkopp

Carl’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • The latest Closing Bell is available now
    By Callum Newman

    Tune in today to watch the latest Closing Bell podcast with Murray Dawes. We discuss gold, the Alphabet (Google) outlook…and more!

  • Iron Ore Stocks: Opportunity if You Have a Strategy
    By James Cooper

    James Cooper digs into the potential iron ore opportunity, a commodity that could reward investors if they’re disciplined. Read on to find out one simple strategy you can apply in this sector.

  • Cash in thanks to billionaire Jim Rogers…NOW
    By Callum Newman

    We don’t know where Trump is taking the world. But we do know the Aussie government game plan. It’s simple… Spend! Spend! Spend! Yes, it’s our tax dollars going out, no doubt some of it due to be wasted and squandered. We can’t stop that. What we can do is own the firm(s) that might be on the receiving end. Here’s an idea…

Primary Sidebar

Latest Articles

  • The latest Closing Bell is available now
  • Iron Ore Stocks: Opportunity if You Have a Strategy
  • Cash in thanks to billionaire Jim Rogers…NOW
  • Lies, Lies and GDP Statistics
  • Special Edition Uranium (Part III): The Western Supply Dilemma

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988